Study Design
This is a prospective non-randomized preliminary study for observing the
effectiveness and safety of using intralesional methylprednisolone to
treat patients in the active phase of Peyronie’s disease. Patients who
applied to our clinic for Peyronie’s disease and who were in the active
phase of the disease between 2018 and 2020 were included in the study.
To confirm that the disease was in the acute phase, we used the
following criteria for inclusion: (1) less than 12 months passed since
the onset of complaints; (2) absence of calcified plaque in penile
duplex doppler ultrasound; (3) symptoms of painful erection; and (4)
recent change in penile curvature. Patients who had completed the acute
phase and progressed to the chronic phase disease stage, who had the
presence of calcified plaque, who had prior medical or surgical
treatment for Peyronie’s disease, who had a history of extra corporeal
shock wave therapy (ESWT), who had hourglass and hinge deformity, and
who were not sexually active were excluded from the study. Apart from
hourglass and hinge deformity, patients with all types of curvature were
included in the study.